Erez Capital

Erez Capital is a venture firm with website, LinkedIn, and Crunchbase footprint, with positioning that suggests a generalist or thematic early-stage investor. The source data does not disclose specific stage, sector, healthcare exposure, or check size detail. The Erez naming, Hebrew for cedar, may signal Israeli founder or geographic connection, suggesting potential cross-border U.S.-Israel investment activity. For healthcare AI founders, Erez should be treated as a generalist early-stage potential investor with no confirmed healthcare specialization unless verified through direct conversation. Plausible check sizing at this profile is $100K to $1M at seed, often as a co-investor though potentially leading smaller rounds. The most likely fit, if any, is for software-style healthcare AI companies with capital-efficient unit economics, particularly Israeli or U.S.-Israeli founders given the likely cross-border ecosystem connection. Founders building biotech, regulated devices, or capital-intensive care delivery requiring specialist healthcare capital should look elsewhere. The firm’s value-add is most credible around U.S.-Israeli ecosystem access, founder coaching, and connection to relevant follow-on capital. Founders building deeply clinical or regulatory-heavy products should look to specialist healthcare investors first. Entry path is LinkedIn outreach to the partners, the website inquiry form, or warm referral from an Israeli or U.S.-Israeli ecosystem operator. Founders should reverse-diligence by asking for recent investments, fund size, ownership targets, and any healthcare exposure before significant pitch preparation. Be honest about the data gap: at this profile, founder time should be limited until clearer signals of thesis alignment surface, and disclosed-thesis healthcare investors should be prioritized first.